Stockreport

Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Merus N.V. - Common Shares  (MRUS) 
Last merus n.v. - common shares earnings: 8/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/mrus
PDF -   51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date-   Encouraging early clin [Read more]